Replimune REPL 深 沪
等待开盘 07-03 09:30:00 美东时间
11.58
+0.360
+3.21%
华盛通- 最 高11.95
- 今 开11.24
- 成交量 283.83万股
- 最 低 11.09
- 昨 收 11.22
- 总市值 9.56亿
- 52周最高 13.24
- 市盈率 静 --
- 换手率 3.44%
- 52周最低 1.50
- 委 比 55.56%
- 总股本 8257.26万
- 历史最高 54.79
- 量 比 0.61
- 振 幅 7.66%
- 历史最低 1.50
- 每 手 1
- 风险率 2.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Four stock-moving events to watch as FDA revives AdComs
The Advisory Committee meetings, a key regulatory step in U.S. drug and MedTech approvals, are making a comeback as the Food and Drug Administration seeks to revisit several controversial decisions ma...
07-02 01:51
美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元
今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元
07-01 10:40
分析师解读医疗企业 Replimune Group（REPL）、Abivax SA 担保ADR（ABVX）及Larimar Therapeutics（LRMR）
3位医疗领域五星分析师近期分别对3只美股医疗保健个股给出看涨评级，相关核心信息如下： Replimune Group（REPL）：摩根大通将其评级上调至买入...
06-30 22:02
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wedbush raised the price target for Replimune Group Inc (NASDAQ:REPL) from $6 to $9. Wedbush analyst Robert Dr...
06-30 21:04
Wedbush Maintains Neutral on Replimune Group, Raises Price Target to $9
Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ:REPL) with a Neutral and raises the price target from $6 to $9.
06-30 20:51
财报速睇 | Replimune 2026财年年度营收0.00亿美元，同比增长0.0%；归母净利润亏损3.14亿美元，同比亏损扩大26.9%
华盛资讯6月29日讯，Replimune公布2026财年年度业绩，公司年度营收0.00亿美元，同比增长0.0%，归母净利润亏损3.14亿美元，同比亏损扩大26.9%。
06-29 23:18
财报速睇 | Replimune 2026财年年度营收0.00亿美元，同比增长0.0%；归母净利润亏损3.14亿美元，同比亏损扩大27.0%
华盛资讯6月29日讯，Replimune公布2026财年年度业绩，公司年度营收0.00亿美元，同比增长0.0%，归母净利润亏损3.14亿美元，同比亏损扩大27.0%。
06-29 23:02
Replimune Group Q4 EPS $(0.76) Misses $(0.71) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.71) by 7.04 percent. This is a 7.32 percent increase over losses of $(0.82) per share from the same period last year.
06-29 20:52
Replimune Group Inc：摩根大通将其评级从中性上调至超配 目标价从8美元上调至17美元
摩根大通将瑞普免疫集团（Replimune Group Inc.，股票代码REPI）的投资评级从“中性”上调至“增持”，同时将该股目标价从8美元上调至17美元...
06-26 23:30
Replimune’s RP1 BLA Resubmission Accepted for Review
Replimune Group ( ($REPL) ) has provided an announcement. On June 26, 2026, Rep...
06-26 20:27
